Drug name - Rinvoq

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47221 ABBVIE INC Tricyclic compounds
Dec, 2030

(8 years from now)

US8962629 ABBVIE INC Tricyclic compounds
Jan, 2031

(8 years from now)

US10981923 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(14 years from now)

US9951080 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(14 years from now)

US11186584 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(14 years from now)

CN102118968A ABBVIE INC Novel Tricyclic Compounds
Sep, 2015

(7 years ago)

CN104592231A ABBVIE INC Novel Tricyclic Compounds
Jan, 2019

(3 years ago)

CN104370909B ABBVIE INC Tricyclic Compounds
Dec, 2030

(8 years from now)

CN109053742A ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

CN104370909A ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

CN102711476A ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

CN102711476B ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

CN109053742B ABBVIE INC Tricyclic Compounds
Dec, 2030

(8 years from now)

IN292307B ABBVIE INC Novel Tricyclic Compounds
Jun, 2029

(6 years from now)

IN201100195P1 ABBVIE INC Novel Tricyclic Compounds
Jun, 2029

(6 years from now)

EP2299821A1 ABBVIE INC Tricyclic Compounds
Jun, 2029

(6 years from now)

EP2299821A4 ABBVIE INC Novel Tricyclic Compounds
Jun, 2029

(6 years from now)

EP2299821B1 ABBVIE INC Tricyclic Compounds
Jun, 2029

(6 years from now)

EP2506716B1 ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

EP2506716A1 ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

EP2506716A4 ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10550126 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10995095 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10597400 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof Oct, 2036

(14 years from now)

US9963459 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof Oct, 2036

(14 years from now)

US10981924 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10519164 ABBVIE INC Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10344036 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US11198697 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10730883 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

Drugs and Companies using UPADACITINIB ingredient

Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.